Published in J Hepatol on July 01, 1998
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol (2001) 3.95
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut (2003) 2.96
Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg (2002) 2.42
Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol (2006) 1.89
The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol (2009) 1.32
Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer (2012) 1.27
High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol (2008) 1.26
High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol (2002) 1.25
Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol (2003) 1.20
Hepatocellular carcinoma: is current therapy really altering outcome? Gut (2002) 1.16
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res (2010) 1.07
Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci (2013) 1.06
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One (2012) 1.03
Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. Biomed Imaging Interv J (2010) 0.98
Interventional therapies for hepatocellular carcinoma. Cancer Imaging (2012) 0.93
Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol (2008) 0.92
Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. Indian J Radiol Imaging (2011) 0.91
Short-term reductions in non-protein respiratory quotient and prealbumin can be associated with the long-term deterioration of liver function after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol (2012) 0.90
Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Ann Surg (2003) 0.90
The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011. J Vasc Interv Radiol (2011) 0.89
Influence of hepatic arterial blockage on blood perfusion and VEGF, MMP-1 expression of implanted liver cancer in rats. World J Gastroenterol (2002) 0.89
Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol (2012) 0.88
Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE. World J Gastroenterol (2002) 0.87
Non-surgical treatment of hepatocellular carcinoma. HPB (Oxford) (2005) 0.87
Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol (2010) 0.87
Embolisation of cancer: what is the evidence? Cancer Imaging (2004) 0.86
Right trisectionectomy for primary liver cancer. World J Gastroenterol (2003) 0.86
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. Biomed Res Int (2016) 0.85
Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol (2009) 0.84
Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. Gastrointest Cancer Res (2011) 0.84
A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2010) 0.84
A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment. J Gastroenterol (2012) 0.83
Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol (2013) 0.83
131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma. World J Gastroenterol (2013) 0.83
Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization. World J Gastroenterol (2008) 0.81
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer (2015) 0.80
Locoregional treatment for hepatocellular carcinoma: The best is yet to come. World J Radiol (2015) 0.80
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest New Drugs (2011) 0.80
Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer (2011) 0.80
A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol (2010) 0.79
Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. World J Gastroenterol (2006) 0.78
Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol (2014) 0.78
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol (2015) 0.78
Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging (2010) 0.78
Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford) (2014) 0.77
Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified? Langenbecks Arch Surg (2007) 0.77
Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep (2014) 0.76
Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. Saudi J Gastroenterol (2014) 0.75
Unresectable hepatocellular carcinoma treated with transarterial chemoembolization: clinical data from a single teaching hospital. Int J Clin Exp Med (2013) 0.75
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol (2016) 0.75
Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma. Oncol Lett (2010) 0.75
Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol (2017) 0.75
Liver transplantation for hepatocellular carcinoma: a single European centre experience. Langenbecks Arch Surg (2004) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol (2005) 5.82
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Induction of tumor necrosis factor alpha expression in human T lymphocytes following ionizing gamma irradiation. J Interferon Cytokine Res (1996) 4.88
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
What is the best similarity measure for motion correction in fMRI time series? IEEE Trans Med Imaging (2002) 4.09
Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell (1991) 3.98
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
The osmotic pressure of globin. Biochem J (1932) 3.69
Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging (2001) 3.25
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (2010) 3.21
A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol (1997) 3.08
Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg (2011) 2.91
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg (1992) 2.76
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
Three-dimensional multimodal brain warping using the demons algorithm and adaptive intensity corrections. IEEE Trans Med Imaging (2001) 2.58
Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol (2000) 2.48
High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology (2001) 2.41
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg (1999) 2.37
Single calcium-dependent potassium channels in clonal anterior pituitary cells. Biophys J (1982) 2.26
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol (2004) 2.24
A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc (1998) 2.21
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol (2006) 2.18
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol (2002) 2.15
Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression. Acta Psychiatr Scand (2011) 2.14
The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol Rev (2000) 2.13
Primary structure of dystrophin-related protein. Nature (1992) 2.09
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04
Randomised clinical trial: enteral nutrition does not improve the long-term outcome of alcoholic cirrhotic patients with jaundice. Aliment Pharmacol Ther (2012) 2.03
Molecular heterogeneity of the fragile X syndrome. Nucleic Acids Res (1991) 2.00
Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99
Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol (2000) 1.95
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol (2009) 1.93
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst (1996) 1.93
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol (2009) 1.92
Cefotaxime-related hypoprothrombinemia in a patient with acute pancreatitis: a case with a possible clue to the pathogenesis. Am J Gastroenterol (1989) 1.92
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer (2001) 1.92
ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys (1991) 1.91
A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol (1990) 1.86
Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol (1998) 1.84
Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg (1998) 1.79
Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain (2009) 1.77
Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group. N Engl J Med (1999) 1.75
Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74
Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg (2002) 1.74
Biliary obstruction caused by portal cavernoma: a study of 8 cases. J Hepatol (1996) 1.74
Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol (2009) 1.72
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.72
Intrahepatic splenosis: imaging features. Abdom Imaging (2000) 1.71
Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med (1982) 1.71
Percutaneous gastrostomy with fluoroscopic guidance: single-center experience in 500 consecutive cancer patients. Radiology (1999) 1.70
Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med (1993) 1.69
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.67
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer (2002) 1.66
Fatty liver hepatitis and cirrhosis in obese patients. Am J Med (1979) 1.66
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer (1985) 1.66
Ascaris lumbricoides infection is associated with protection from cerebral malaria. Parasite Immunol (2000) 1.65
Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg (1995) 1.64
Trends and differential use of assistive technology devices: United States, 1994. Adv Data (1997) 1.64
Incomplete septal cirrhosis: histopathological aspects. Histopathology (1988) 1.63
Radiofrequency liver ablation: experimental comparative study of water-cooled versus expandable systems. AJR Am J Roentgenol (2001) 1.61
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol (2002) 1.61
Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend (1999) 1.60
Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas: preliminary correlations with local control and overall survival. Int J Radiat Oncol Biol Phys (1993) 1.60
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59
Arsenic and non-cirrhotic portal hypertension. A report of eight cases. J Hepatol (1990) 1.59
Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol (2005) 1.59
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer (2005) 1.58
Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst Rev (2006) 1.58
Caspase-3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo. Proc Natl Acad Sci U S A (1998) 1.56
The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol (2004) 1.56
Modulation of synapse formation by cyclic adenosine monophosphate. Science (1983) 1.56
Perhydrohistrionicotoxin: a potential ligand for the ion conductance modulator of the acetylcholine receptor. Proc Natl Acad Sci U S A (1977) 1.55
The effect of acute severe illness on CD4+ lymphocyte counts in nonimmunocompromised patients. Arch Intern Med (2000) 1.55
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol (2002) 1.55
Biliary symptoms and complications more than 8 years after endoscopic sphincterotomy for choledocholithiasis. Gastroenterology (1996) 1.54